Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Authors:
- Patrick M. FordePFPatrick M. Forde
- Jamie E. ChaftJCJamie E. Chaft
- Kellie N. SmithKSKellie N. Smith
- Valsamo AnagnostouVAValsamo Anagnostou
- Tricia R. CottrellTCTricia R. Cottrell
- Matthew D. HellmannMHMatthew D. Hellmann
- Marianna ZahurakMZMarianna Zahurak
- Stephen C. YangSYStephen C. Yang
- David R. JonesDJDavid R. Jones
- Stephen BroderickSBStephen Broderick
- Richard J. BattafaranoRBRichard J. Battafarano
- Moises J. VelezMVMoises J. Velez
Top Cited Papers
- 24 May 2018
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 378 (21) , 1976-1986
Abstract
Antibodies that block programmed death 1 (PD-1) protein improve survival in patients with advanced non–small-cell lung cancer (NSCLC) but have not been tested in resectable NSCLC, a condition in which little progress has been made during the past decade. In this pilot study, we administered two preoperative doses of PD-1 inhibitor nivolumab in adults with untreated, surgically resectable early (stage I, II, or IIIA) NSCLC. Nivolumab (at a dose of 3 mg per kilogram of body weight) was administered intravenously every 2 weeks, with surgery planned approximately 4 weeks after the first dose. The primary end points of the study were safety and feasibility. We also evaluated the tumor pathological response, expression of programmed death ligand 1 (PD-L1), mutational burden, and mutation-associated, neoantigen-specific T-cell responses. Neoadjuvant nivolumab had an acceptable side-effect profile and was not associated with delays in surgery. Of the 21 tumors that were removed, 20 were completely resected. A major pathological response occurred in 9 of 20 resected tumors (45%). Responses occurred in both PD-L1–positive and PD-L1–negative tumors. There was a significant correlation between the pathological response and the pretreatment tumor mutational burden. The number of T-cell clones that were found in both the tumor and peripheral blood increased systemically after PD-1 blockade in eight of nine patients who were evaluated. Mutation-associated, neoantigen-specific T-cell clones from a primary tumor with a complete response on pathological assessment rapidly expanded in peripheral blood at 2 to 4 weeks after treatment; some of these clones were not detected before the administration of nivolumab. Neoadjuvant nivolumab was associated with few side effects, did not delay surgery, and induced a major pathological response in 45% of resected tumors. The tumor mutational burden was predictive of the pathological response to PD-1 blockade. Treatment induced expansion of mutation-associated, neoantigen-specific T-cell clones in peripheral blood. (Funded by Cancer Research Institute–Stand Up 2 Cancer and others; ClinicalTrials.gov number, NCT02259621.)Keywords
Funding Information
- International Association for the Study of Lung Cancer
- LUNGevity Foundation
- MacMillan Foundation
- Lung Cancer Foundation of America
- National Cancer Institute (CA006973, CA121113, CA180950, CA193145, P30 CA006973, P30 CA008748, R01 CA142779, T32 CA193145)
- ECOG-ACRIN
- Commonwealth Foundation
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Bristol-Myers Squibb
- Bloomberg–Kimmel Institute for Cancer Immunotherapy
- Stand Up To Cancer (SU2C-AACR-DT1012)
This publication has 31 references indexed in Scilit:
- Palindromic Nucleotide Analysis in Human T Cell Receptor RearrangementsPLOS ONE, 2012
- Comprehensive genomic characterization of squamous cell lung cancersNature, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant ChemotherapyJournal of Thoracic Oncology, 2012
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune EscapeScience Translational Medicine, 2012
- Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy?Clinical Cancer Research, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative GroupJournal of Clinical Oncology, 2008
- The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant TumoursJournal of Thoracic Oncology, 2007
- Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cellsBlood, 2007